Izraēla - ivrits - Ministry of Health

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride

Izraēla - ivrits - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

Izraēla - ivrits - Ministry of Health

unipharm ltd, israel - alendronic acid as sodium - טבליה - alendronic acid as sodium 10 mg - alendronic acid - alendronic acid - treatment of osteoporosis in postmenopausal women: maxibone is indicated for the treatment of osteoporosis to prevent fractures, including those of the hip, wrist and spine ( vertebral compression fractures). prevention and treatment of glucocorticoid-induced osteoporosis: maxibone is indicated for the prevention and treatment of glucocorticoid-induced osteoporosis in men and women. for the treatment of osteoporosis in men.

Izraēla - ivrits - Ministry of Health

gilead sciences israel ltd - lenacapavir as sodium - טבליות מצופות פילם - lenacapavir as sodium 300 mg - lenacapavir

Izraēla - ivrits - Ministry of Health

gilead sciences israel ltd - lenacapavir as sodium - תמיסה להזרקה - lenacapavir as sodium 309 mg/ml - lenacapavir

Izraēla - ivrits - Ministry of Health

eli lilly israel ltd, israel - teriparatide - תמיסה להזרקה - teriparatide 250 mcg/ml - teriparatide - teriparatide - treatment of postmenopausal women with osteoporosis at high risk for fracture:forteo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. in postmenopausal women with osteoporosis, forteo increases bmd reduces the risk of vertebral and nonvertebral fractures . increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture :forteo is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy . treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture:forteo is indicated for the treatment of men and women with osteopo

Izraēla - ivrits - Ministry of Health

teva pharmaceutical industries ltd, israel - alendronic acid as monohydrate - טבליה - alendronic acid as monohydrate 10 mg - alendronic acid - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip, wrist and spine (vertebral compression fractures).for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women. for the treatment to increase bone mass in men with osteoporosis.

Izraēla - ivrits - Ministry of Health

teva pharmaceutical industries ltd, israel - alendronic acid as monohydrate - טבליה - alendronic acid as monohydrate 10 mg - alendronic acid - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip, wrist and spine (vertebral compression fractures).for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women. for the treatment to increase bone mass in men with osteoporosis.

Izraēla - ivrits - Ministry of Health

merck sharp & dohme israel ltd - alendronic acid as sodium 10 mg - tablets - alendronic acid - treatment of osteoporosis in postmenopausal women: fosalan is indicated for the treatment of osteoporosis in postmenopausal women to prevent fractures including those of the hip and spine ( vertebral compression fractures). for the treatment of osteoporosis in men. prevention and treatment of glucocorticoid-induced osteoporosis in postmenopausal women not receiving estrogen.

Izraēla - ivrits - Ministry of Health

novartis israel ltd - zoledronic acid - תמיסה לאינפוזיה - zoledronic acid 5 mg / 100 ml - zoledronic acid - zoledronic acid - treatment of paget's disease of the bone. treatment of osteoporosis : - in post-menopausal women - in men at increased risk of fracture including those with a recent low-trauma hip fracture.treatment and prevention of glucocorticoid-induced osteoporosis.prevention of postmenopausal osteoporosis in women for whom bisphosphonate therapy is indicated.